Subscribe to our Newsletters !!
In the Pharmaceutical industry, maintaining asepti
Labs today face mounting pressure to cut carbon em
Dr. Mohammed Enayat’s recent testimony on his ag
The life science group Sartorius has successfully
30th June, 2025 Mumbai: Alembic Pharmaceuticals Li
Since it’s an ingredient in so many foods, you h
In our cover story, we shine a spotlight on “ The Magazine
Dr Reddy’s Laboratories on Friday said it has approached drugs regulator DCGI for emergency use authorisation (EUA) for COVID-19 vaccine Sputnik V.
As part of this review process, the medication major will present the safety profile of phase 2 study, and interim information of phase 3 trial, which is expected to be complete by February 21, 2021, Dr Reddy’s said in a statement.
In September last year, the Hyderabad-based firm partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.
The vaccine is undergoing phase 3 clinical trial in India. The Drugs Controller General of India (DCGI) has already given the EUA nod for two COVID-19 vaccines — Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca, being fabricated by Serum Institute of India in Pune.
The vaccines are being administered to frontline workers across the country. Sputnik V has demonstrated an efficacy rate of 91.6 percent in the interim analysis of phase 3 clinical trial, which contained information on 19,866 volunteers in Russia, the announcement said.
The vaccine also maintained a consistent efficacy at 91.8 percent even among the group of 2,144 volunteers over 60 years old. “The efficacy of Sputnik V was reported to be 91.6 per cent by the Lancet, which is an impressive development in the struggle against COVID-19. The initiation of the EUA process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India,” Dr Reddy’s Laboratories Co-chairman and Managing Director G V Prasad explained.
Sputnik V has already receivedapproval in 26 countries and has been administered to more than 2 million individuals globally.